Summary
The AI claims describe a patient savings program eligibility and administration details, which are not present in the provided FDA-approved Vascepa prescribing information excerpts. Therefore, the claims cannot be verified against the label and are treated as unsupported by the provided label information.
Category Scores
Accurate Statements
Unsupported Statements
The Vascepa Savings Program is a patient assistance program designed to help eligible patients access Vascepa at a reduced cost.
The provided Vascepa FDA-approved prescribing information excerpts do not mention any savings program, patient assistance program, eligibility criteria, or reduced-cost access.
The Vascepa Savings Program is administered by Amarin Pharmaceuticals, the manufacturer of Vascepa.
The provided Vascepa FDA-approved prescribing information excerpts do not mention any program administrator or Amarin's role in administering a savings program.
To be eligible for the Vascepa Savings Program, patients must be at least 18 years old.
The provided Vascepa FDA-approved prescribing information excerpts do not include any eligibility criteria for a savings program.
To be eligible for the Vascepa Savings Program, patients must have a household income at or below 200% of the Federal Poverty Level (FPL).
The provided Vascepa FDA-approved prescribing information excerpts do not include any eligibility criteria for a savings program.
To be eligible for the Vascepa Savings Program, patients must have commercial insurance, Medicare Part D, or Medicaid.
The provided Vascepa FDA-approved prescribing information excerpts do not include any eligibility criteria for a savings program.
To be eligible for the Vascepa Savings Program, patients must have a diagnosis of high triglycerides or a history of cardiovascular events such as heart attacks or strokes.
The provided Vascepa FDA-approved prescribing information excerpts include labeled indications but do not describe savings program eligibility criteria.
To be eligible for the Vascepa Savings Program, patients must be currently taking Vascepa or be prescribed Vascepa by their healthcare provider.
The provided Vascepa FDA-approved prescribing information excerpts do not describe savings program eligibility criteria.
Contradictions
Important Omissions
Any label-supported details about the Vascepa Savings Program (existence, purpose, administrator, and eligibility criteria) are not provided in the supplied prescribing information excerpts.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Low
The evaluated claims concern a savings program and do not include dosing, contraindications, warnings, or safety risk statements from the provided label.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
High |
Recommendation
Not Aligned
Primary Issue
All claims relate to a patient savings program and are not supported by the provided FDA-approved Vascepa prescribing information excerpts.
Suggested Improvement
Remove savings-program eligibility/administration claims unless supported by label text supplied in the prompt; otherwise, clearly attribute such details to a non-label source separate from the FDA prescribing information.